Health care setting | Exclusion criteria: All sub-studies: female patients as regards erectile dysfunction medicines(G04BE) | Number: enrolled (evaluated) | Sex (m/f) | Age (Median, Interquartile range Q1-Q3): all patients; (m/f) | Medicines classes (WHO ATC) |
---|---|---|---|---|---|
Ambulatory Yerevan (Armenia) | Patients of all age groups with mild to moderate infections | 50 | 24/26 | 33 (20.5–45.5) (34 (19–49)/ /31 (19.5–42.5) | Antibiotics (J01) |
Ambulatory Zagreb & Pula (Croatia) | Patients <14, > 65 y; | 71 (70)a | 34/36 | 47 (35–59) (48 (37.7–58.5)/ 43.5 (30.5–56.5) | Anti-obesity Preparations, Excl. Diet Products (A08), Anabolic Agents for Systemic Use (A14), Diuretics (C03), Sex Hormones and Modulators of the Genital System (G03), Urologicals (G04), Psycho-analeptics (N06) |
Ambulatory Rome (Italy) | Patients <14, > 65 y | 60 (60) | 60 m | m: 32 (25.4–38.6) | Anabolic Agents for Systemic Use, Diuretics, Sex Hormones and Modulators of the Genital System, Urologicals |
Pilot-study Ambulatory Sports out-patient clinic Belgrade (Serbia) | Patients <14, > 65 y; | 105 (105) | 79/26 | 33 (27–39) (33 (26.5–39.5)/ 33 (28–38)) | Anti-obesity Preparations, anabolic agents for systemic use, Diuretics, Sex Hormones and Modulators of the Genital System |
In-patient Aalst (Belgium) | Patients <14, > 65 y; | 42 42 | 23/19 | 42 (27.4–56.7) (45 (27.3–53.8) 42 (30–54) | Anti-obesity Preparations, Anabolic Agents for Systemic Use, Diuretics, Sex Hormones and Modulators of the Genital System, Urologicals, Psycho-analeptics |
In-patient Reykjavík (Iceland) | Patients <14, > 65 y; | 149 (149) | 51/98 | 47 (32.5– 61.5) (46 (31.5–60.5)/ 48 (34–62) | Anti-obesity Preparations |